加巴喷丁联合阿片类用药与乳腺癌术后呼吸、心血管及阿片相关不良事件风险的研究
Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer
作者：Jyun‐Heng Lai、Anton L V Avanceña、Juan P Cata、Jamie C. Barner、Sharon H. Giordano、Chanhyun Park、Hui Zhao、Kirk E. Evoy、John K. Lin、Jennifer C. Spencer、Mariana Chavez‐MacGregor、Kelly K. Hunt、Kerollos Nashat Wanis
单位：Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.；Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.；Department of Anesthesiology and Perioperative Medicine, Division of Anesthesiology, Critical Care Medicine, and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.；Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.；Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.；Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.；Division of Pharmacotherapy and Translational Sciences, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.；Pharmacotherapy Education and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
摘要
《临床药理学与治疗学》2026年8月22日在线发表一项研究，评估乳腺癌术后加巴喷丁联合阿片类药物用药与呼吸、心血管及阿片相关不良事件风险。研究结果提示联合用药可能存在安全隐患，需关注用药方案与监测。该文为EarlyView早期预览，尚未正式排版。
AI 主编 · 推荐理由推荐理由
该研究直接关联术后镇痛联合用药安全，提示注册与临床研发中需评估加巴喷丁类联合使用的风险获益，质量管理与药物警戒部门应关注此证据，调整监测策略。